jCyte

jCyte is a private, pre-revenue biotech advancing a proprietary platform of retinal progenitor cell (RPC) therapies for inherited retinal diseases. Its lead asset, jCell, is in late-stage clinical development for retinitis pigmentosa, with a pivotal Phase 3 trial (JC02-88) now enrolling. The company leverages its RPC platform to pursue multiple ophthalmic indications, including diabetic retinopathy, positioning it in the high-need cell and gene therapy space for blindness. Leadership combines strong scientific co-founders with experienced biotech executives to drive clinical and corporate strategy.

Proprietary platform using allogeneic human retinal progenitor cells (jCell) delivered via intravitreal injection. The cells are postulated to exert a paracrine effect, secreting factors to protect and potentially restore function in degenerating retinas.

jCyte competes in the retinal disease space with gene therapy companies (e.g., Spark Therapeutics' Luxturna for RPE65 mutations) and other regenerative approaches, including stem cell therapies from companies like Lineage Cell Therapeutics. Its key differentiation is the intravitreal delivery method and a paracrine mechanism targeting a broad RP population, irrespective of genetic mutation.